Even though the immuno-oncology (IO) era has achieved many successes, some signs of
research development deceleration are arising. Recently, the number of FDA …

Summary In 2010, modified RECIST (mRECIST) criteria were proposed as a way of
adapting the RECIST criteria to the particularities of hepatocellular carcinoma (HCC). We …

Background Pembrolizumab has shown improved progression-free survival versus
chemotherapy in patients with newly diagnosed microsatellite instability-high or mismatch …

PURPOSE Small-cell lung cancer (SCLC) is an aggressive malignancy with limited
treatments. Delta-like ligand 3 (DLL3) is aberrantly expressed in most SCLC. Tarlatamab …

Tumour cells evade immune surveillance by upregulating the surface expression of
programmed death-ligand 1 (PD-L1), which interacts with programmed death-1 (PD-1) …

Hepatocellular carcinoma (HCC) is the fourth leading cause of cancer-related mortality
worldwide.(1, 2) This neoplasm has some unique characteristics. It occurs in most cases …

Head and neck cancers, including those of the lip and oral cavity, nasal cavity, paranasal
sinuses, oropharynx, larynx and nasopharynx represent nearly 700,000 new cases and …

Novel patterns of response and progression to immunotherapy have been reported that are
not observed with conventional cytotoxic or targeted anticancer treatments. A major …

Tumours respond differently to immunotherapies compared with chemotherapeutic drugs,
raising questions about the assessment of changes in tumour burden—a mainstay of …

Recent evidence indicates that ionizing radiation can enhance immune responses to
tumors. Advances in radiation delivery techniques allow hypofractionated delivery of …